🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Hereditary Cancer Syndrome

An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors NCT07371663Phase 1, Phase 23 sites📍 Beijing📍 Zhengzhou📍 Hangzhou Beijing Tide Pharmaceutical Co., Ltd · Tests: TCC1727 tablet 90mg, TCC1727 tablet 120mg, TCC1727 tablet 160mg, benmelstobart Injection Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer NCT06088030Phase 21 site📍 Guangzhou Yang Li · Tests: Arsenic trioxide Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford NCT01793168n/a1 site📍 Sioux Falls Sanford Health 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors NCT07557225NA1 site📍 Beijing Peking University First Hospital · Tests: 18F-T2 PET/CT HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas NCT05331105Phase 21 site📍 Shanghai Shanghai Kechow Pharma, Inc. · Tests: HL-085 A Study Comparing the Necessity of a Second Transurethral Resection in High-Risk Non-Muscle-Invasive Bladder Cancer Patients With Negative Results From Post-Initial Resection Urine Genome-Wide Low-Depth Sequencing NCT07036731NA1 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: Urine biomarker -Guided without reTURBT Duodenal Polyposis Classification in FAP NCT07199127n/a2 sites📍 Milan📍 Milan Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Tests: DRACO Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency NCT06090669Phase 11 site📍 Bethesda National Cancer Institute (NCI) · Tests: TruSight Oncology, imatinib EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection NCT03266653Phase 28 sites📍 Los Angeles📍 San Francisco📍 Baltimore New York Medical College · Tests: cytotoxic t-lymphocytes Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism NCT00929006EARLY Phase 11 site📍 Charlottesville University of Virginia · Tests: Micronized progesterone suspension, Placebo PTEN Hamartoma Tumor Syndrome Pediatric Patient Registry NCT06462430n/a1 site📍 Istanbul Yale University Provider-Mediated Communication of Genetic Testing Results to At-Risk Relatives of Cancer Patients to Improve Genetic Counseling and Testing Rates, Family HOPE Study NCT05772130NA1 site📍 Duarte City of Hope Medical Center · Tests: Best Practice, Electronic Health Record Review, Personal Contact, Survey Administration Natural History Study of Parathyroid Disorders NCT04969926n/a1 site📍 Bethesda National Institute of Diabetes and Digestive and Kidney Dis… Impact of Environmental Exposures on Tumor Risk in SDHx-mutation Carriers NCT06408402n/a20 sites📍 Angers📍 Besançon📍 Bron Assistance Publique - Hôpitaux de Paris Study of the Disease Process of Lymphangioleiomyomatosis NCT00001465n/a1 site📍 Bethesda National Heart, Lung, and Blood Institute (NHLBI) · Tests: Toshibia Aquilion One CT Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas NCT05253131Phase 21 site📍 Birmingham University of Alabama at Birmingham · Tests: Selumetinib + ZEN-3694 ± Durvalumab Acute Effects of Ketone Monoester Co-ingestion With Dietary Protein on Whole-body Phenylalanine Oxidation, Phenylalanine Retention, and Myofibrillar Protein Breakdown Following Resistance Exercise in Young Males. NCT07884539NA1 site📍 Montreal McGill University · Tests: Ketone Monoester + Dietary Protein (KET+PRO), Dietary Protein (PRO), Resistance Exercise Glioma Developmental and HyperActive Ras Tumor (DHART) Board NCT05489783n/a7 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center Cancer Predisposition Testing by Family-based Whole-genome Sequencing (WGS) in Every Child With Newly Diagnosed Cancer NCT04903782n/a3 sites📍 Newcastle📍 Sydney📍 Sydney Sydney Children's Hospitals Network · Tests: Family-based whole genome sequencing Lean Beef as Part of a Healthy Meal Plan in Adolescents With Polycystic Ovary Syndrome (PCOS)/Polyendocrine Metabolic Ovarian Syndrome (PMOS) NCT07780188NA1 site📍 College Station Texas A&M University · Tests: Beef+ Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1 NCT07102394Phase 11 site📍 Baltimore Johns Hopkins University · Tests: Imlygic Treatment With Full-spectrum Cannabis Extract of Refractory Epilepsy Associated With Tuberous Sclerosis Complex (TSC) NCT07403266Phase 31 site📍 Madrid Oils4Cure · Tests: YCJ-01 Full Spectrum cannbis Extract, Placebo Mirdametinib in Patients With Advanced NF1-mutant Melanoma NCT07237100Phase 21 site📍 San Francisco Kevin Kim, MD · Tests: Mirdametinib Chatbot to Maximize Hereditary Cancer Genetic Risk Assessment NCT05562778NA4 sites📍 Brooklyn📍 New York📍 New York Weill Medical College of Cornell University · Tests: Chatbot Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer NCT01137643n/a1 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: biologic sample preservation procedure, cytology specimen collection procedure Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas NCT06502171Phase 18 sites📍 Birmingham📍 Los Angeles📍 Washington D.C. Girish Dhall, MD · Tests: Cabozantinib Oral Tablet, Selumetinib Oral Capsule Registry for Adults With Plasma Cell Disorders (PCD's) NCT03717844n/a1 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1) NCT06507748NA2 sites📍 Washington D.C.📍 Bethesda National Cancer Institute (NCI) · Tests: AlgometRx Nociometer(R) FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC NCT06788990Phase 2, Phase 3231 sites📍 Birmingham📍 Phoenix📍 La Jolla Bicara Therapeutics · Tests: Ficerafusp alfa, Pembrolizumab (KEYTRUDA®), Placebo Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC NCT05491525Phase 2, Phase 338 sites📍 Little Rock📍 Orange📍 Aurora Urovant Sciences GmbH · Tests: Vibegron
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy